Oscar Larrainzar was tethered to a dialysis machine for years, unable to do something as simple as take his daughter swimming. Twelve months after surgeons at UCLA performed the world’s first human bladder transplant, he is back at work and has finally taken that swim — the first time his daughter has seen her father in a pool since she was an infant.
The milestone was reported by News Medical Life Sciences, which covered the one-year follow-up on the June 2025 procedure. The detail that sets this case apart from prior experimental work: surgeons did not just transplant the bladder in isolation. They combined a donor kidney and a donor bladder into a single, coordinated operation — a pairing that had never been attempted in a human being before.
Why a kidney and bladder had to go in together
Larrainzar had lost most of his bladder function to a condition that left him unable to store or pass urine normally. Standard kidney transplants had not been an option because a donated kidney requires a functioning bladder to drain into — without one, the new organ would fail almost immediately. Surgeons led by Dr. Inderbir Gill and Dr. Nima Nassiri at UCLA designed the combined procedure specifically to solve that catch-22.
The non-obvious detail buried in the follow-up: the transplanted bladder was connected using a novel surgical technique that preserved a segment of the donor’s attached blood vessels, reducing the risk of the organ losing its blood supply — one of the biggest failure points in experimental organ transplants. That vascular preservation approach is now being studied as a potential template for future cases.
Before the surgery, Larrainzar spent hours each week on dialysis, which filters waste from the blood when the kidneys cannot. Dialysis keeps patients alive but imposes strict limits — on diet, travel, physical activity, and, as Larrainzar’s story illustrates, the ordinary moments of parenthood. The bladder transplant, by giving his new donor kidney a functional place to drain, made dialysis unnecessary entirely.
Larrainzar’s recovery by the numbers
At the one-year mark, Larrainzar’s transplanted kidney is producing urine normally and his bladder function has stabilized. He returned to full-time work, which his medical team described as a strong indicator of overall recovery quality. No major rejection episodes have been reported publicly in the follow-up coverage, though he remains on immunosuppressant medication — standard protocol for any transplant recipient — to prevent his immune system from attacking the donor organs.
The swim with his daughter was not a planned medical milestone. It emerged as a personal one: a father doing something ordinary that his illness had taken away. That kind of quality-of-life recovery is precisely what the UCLA team said they were aiming for when they moved from animal models to a human patient.
Prior to this surgery, bladder replacement options were largely limited to creating a substitute pouch from a section of the patient’s own intestine — a procedure called a neobladder or ileal conduit. Those options carry their own complications, including mucus production, infection risk, and the need for self-catheterization. A transplanted biological bladder, if it functions as it has in Larrainzar’s case, could eventually offer a cleaner alternative for patients whose bladders are non-functional from birth defects, cancer, trauma, or neurological disease.
What comes next for bladder transplant surgery
UCLA has indicated plans to expand the procedure to a small cohort of additional patients, pending continued positive outcomes in Larrainzar’s case. The surgical team is working to refine patient selection criteria — particularly identifying which candidates have both the kidney failure and bladder failure combination that makes the dual-organ approach worthwhile.
Regulatory and ethical review processes will shape how quickly the technique scales. Organ transplantation in the U.S. is governed by the Organ Procurement and Transplantation Network (OPTN), which sets allocation and protocol standards. Any expansion of bladder transplant surgery will require the team to submit outcomes data and receive formal approval before it becomes a listed transplant procedure nationwide.
For the estimated tens of thousands of Americans living with end-stage bladder dysfunction alongside kidney failure, the Larrainzar case offers the first real human proof of concept. This is not a treatment yet available at most transplant centers — but one year of a thriving patient is the clearest evidence so far that it could be.
Medical advances like this one sit alongside other stories of systems quietly changing for patients — a nonprofit has now erased $40 billion in medical debt for Americans who couldn’t afford care, a reminder that access and innovation have to move together. And for anyone tracking organ transplant surgery broadly, right-to-repair battles in other industries hint at a wider cultural push for patients and consumers to have more control over the systems that sustain them.
The UCLA team’s next published data on the bladder transplant cohort is expected later in 2026. If even a handful of additional patients show comparable one-year outcomes, the procedure’s path from experimental to standard of care will accelerate considerably.
